<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20250212031431&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20250212031431&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 12 Feb 2025 08:14:33 +0000</lastbuilddate>
<pubDate>Tue, 11 Feb 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Author Correction: Traction force microscopy of cardiomyocytes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39934356/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212031431&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Feb 11. doi: 10.1038/s41569-025-01139-w. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39934356/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212031431&v=2.18.0.post9+e462414">39934356</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01139-w>10.1038/s41569-025-01139-w</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39934356</guid>
<pubDate>Tue, 11 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Maia Lyall</dc:creator>
<dc:date>2025-02-11</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Author Correction: Traction force microscopy of cardiomyocytes</dc:title>
<dc:identifier>pmid:39934356</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01139-w</dc:identifier>
</item>
<item>
<title>Baseline characteristics and outcomes of rheumatic mitral valve disease: the EURObservational Research Programme Valvular Heart Disease II Survey</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39932741/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212031431&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Compliance with guideline recommendations for intervention is poor overall in patients with rheumatic valve disease. Concerted educational efforts are needed to improve the management of this vulnerable patient cohort.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 11:ehaf050. doi: 10.1093/eurheartj/ehaf050. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Rheumatic heart disease is the commonest acquired cardiovascular disease worldwide. About 20 years have elapsed since the original Euro Heart Survey on valvular heart disease (VHD) was conducted with multiple changes in practice due to advances in treatment techniques. In this study, we aimed to analyse the management of patients with severe native valve disease or those with previous valvular intervention in comparison with existing European Society of Cardiology guidelines.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The European Society of Cardiology VHD II registry is an international, prospective, longitudinal multicentre, observational study, which was conducted in 222 centres. The registry included patients with severe native VHD or with previous valvular intervention. Follow-up was undertaken at 6 months at the investigating centre or by telephone.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Amongst patients recruited in the European Society of Cardiology VHD II registry, 470 had severe rheumatic mitral valve disease and 332 had previous rheumatic mitral valve intervention. Amongst the patients with Class I recommendation for intervention, it was undertaken in only 70%. Adherence to guideline recommendations was more in patients with native VHD than in those with previous intervention. Total mortality was 1.5% in hospital and 3.5% at 6 months follow-up. Independent predictors of death at 6 months were age, chronic pulmonary disease, New York Heart Association Classes III and IV at presentation, liver dysfunction, and previous myocardial infarction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Compliance with guideline recommendations for intervention is poor overall in patients with rheumatic valve disease. Concerted educational efforts are needed to improve the management of this vulnerable patient cohort.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39932741/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212031431&v=2.18.0.post9+e462414">39932741</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf050>10.1093/eurheartj/ehaf050</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39932741</guid>
<pubDate>Tue, 11 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Magdy Abdelhamid</dc:creator>
<dc:creator>Amir M Abdel Meged</dc:creator>
<dc:creator>Bernard Prendergast</dc:creator>
<dc:creator>Francisco E Calvo-Iglesias</dc:creator>
<dc:creator>Salma M Taha</dc:creator>
<dc:creator>Ghada A Kazamel</dc:creator>
<dc:creator>Mostafa M Abdrabou</dc:creator>
<dc:creator>Maiy H El Sayed</dc:creator>
<dc:creator>Minna M Kylmala</dc:creator>
<dc:creator>Olga B Irtyuga</dc:creator>
<dc:creator>Alec S Vahanian</dc:creator>
<dc:creator>Bernard Iung</dc:creator>
<dc:creator>Cécile Laroche</dc:creator>
<dc:date>2025-02-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Baseline characteristics and outcomes of rheumatic mitral valve disease: the EURObservational Research Programme Valvular Heart Disease II Survey</dc:title>
<dc:identifier>pmid:39932741</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf050</dc:identifier>
</item>
<item>
<title>Scpep1 inhibition attenuates myocardial infarction-induced dysfunction by improving mitochondrial bioenergetics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39932164/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212031431&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Scpep1 deficiency mitigates MI by improving Pex3-mediated mitochondrial fission and subsequent cardiomyocyte apoptosis. Scpep1 constitutes a potential therapeutic target for attenuating MI.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 11:ehaf032. doi: 10.1093/eurheartj/ehaf032. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Myocardial infarction (MI) is an ischaemic cardiovascular disease associated with increased morbidity and mortality. Previous studies have suggested that serine carboxypeptidase 1 (Scpep1) is involved in vascular diseases; however, its role in cardiac diseases remains unclear. This study aims to explore the role of Scpep1 in regulating cardiac homeostasis during MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The impact of Scpep1 deficiency or cardiac-specific knock-down and Scpep1 overexpression on heart function was evaluated in mice with MI. Its downstream functional mediators of Scpep1 were elucidated using proteomic analysis and confirmed by employing loss- and gain-of-function strategies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Circulating and cardiac Scpep1 levels were up-regulated in mice with MI. Genetic ablation or cardiac-specific knock-down of Scpep1 alleviated MI-induced cardiac dysfunction and damage in mice. In contrast, cardiac-specific Scpep1 overexpression aggravated these adverse effects. Mechanistically, Scpep1 exacerbated MI-induced cardiac dysfunction and damage by impaired mitochondrial bioenergetics via binding to Pex3 to promote its degradation, ultimately contributing to mitochondrial fission and apoptosis. Moreover, the expressional profiles of Scpep1 in plasma samples and heart tissues of patients with MI or ischaemic cardiomyopathy were in line with those observed in the mouse models. In addition, pharmaceutical inhibition of Scpep1 notably improved MI-induced cardiac dysfunction and damage by improving mitochondrial fragmentation and bioenergetics post-MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Scpep1 deficiency mitigates MI by improving Pex3-mediated mitochondrial fission and subsequent cardiomyocyte apoptosis. Scpep1 constitutes a potential therapeutic target for attenuating MI.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39932164/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212031431&v=2.18.0.post9+e462414">39932164</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf032>10.1093/eurheartj/ehaf032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39932164</guid>
<pubDate>Tue, 11 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Guilin Chen</dc:creator>
<dc:creator>Jing Gan</dc:creator>
<dc:creator>Fan Wu</dc:creator>
<dc:creator>Zengxian Zhou</dc:creator>
<dc:creator>Zikun Duan</dc:creator>
<dc:creator>Ke Zhang</dc:creator>
<dc:creator>Songxue Wang</dc:creator>
<dc:creator>Hua Jin</dc:creator>
<dc:creator>Yulin Li</dc:creator>
<dc:creator>Chi Zhang</dc:creator>
<dc:creator>Zhuofeng Lin</dc:creator>
<dc:date>2025-02-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Scpep1 inhibition attenuates myocardial infarction-induced dysfunction by improving mitochondrial bioenergetics</dc:title>
<dc:identifier>pmid:39932164</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf032</dc:identifier>
</item>
<item>
<title>Takotsubo is an acute myocardial ischaemic syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39932154/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212031431&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 11:ehaf020. doi: 10.1093/eurheartj/ehaf020. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39932154/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212031431&v=2.18.0.post9+e462414">39932154</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf020>10.1093/eurheartj/ehaf020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39932154</guid>
<pubDate>Tue, 11 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Robert Sykes</dc:creator>
<dc:creator>Daniel T Y Ang</dc:creator>
<dc:creator>Colin Berry</dc:creator>
<dc:date>2025-02-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Takotsubo is an acute myocardial ischaemic syndrome</dc:title>
<dc:identifier>pmid:39932154</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf020</dc:identifier>
</item>
<item>
<title>SMC Abca1 and Abcg1 Deficiency Enhances Urinary Bladder Distension but Not Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39931819/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212031431&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: We uncover a new role of SMC cholesterol efflux pathways in suppressing α(1)-AR-mediated vasoconstriction and bladder SMC transdifferentiation, decreasing urinary bladder distension. Our data may provide a mechanistic link for the association between urinary bladder distension and diabetes in humans, particularly because diabetes is associated with decreased cholesterol efflux. SMC-Abca1/Abcg1 deficiency did not affect atherosclerotic lesion size or plaque composition, presumably...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Feb 11. doi: 10.1161/CIRCRESAHA.124.325103. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Smooth muscle cells (SMCs) regulate blood flow distribution via vasoconstriction mediated by α-ARs (α-adrenergic receptors). Plasma membrane cholesterol accumulation affects α<sub>1</sub>-AR signaling and promotes loss of SMC contractile markers in vitro. ABCA1 and ABCG1 (ATP-binding cassette transporter A1 and G1) mediate cholesterol efflux to HDL (high-density lipoprotein). ABCA1/ABCG1 show high expression in medial and low expression in intimal SMCs of atherosclerotic plaques. The role of ABCA1 and ABCG1 in SMC-mediated vasoconstriction and atherogenesis remains poorly understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We generated mice with SMC-specific <i>Abca1/Abcg1</i> deficiency on the low-density lipoprotein receptor-deficient (<i>Ldlr</i><sup><i>-</i></sup><sup><i>/</i></sup><sup><i>-</i></sup>) background by crossbreeding <i>Abca1</i><sup><i>fl/fl</i></sup><i>Abcg1</i><sup><i>fl/fl</i></sup><i>Ldlr</i><sup><i>-/-</i></sup> mice with <i>Myh11Cre</i><sup><i>ERT2</i></sup> transgenic mice. To induce SMC cholesterol accumulation and atherogenesis, we fed <i>Myh11Cre</i><sup><i>ERT2</i></sup><i>Abca1</i><sup><i>fl/fl</i></sup><i>Abcg1</i><sup><i>fl/fl</i></sup><i>Ldlr</i><sup><i>-/-</i></sup>, <i>Myh11Cre</i><sup><i>ERT2</i></sup><i>Abca1</i><sup><i>fl/fl</i></sup><i>Ldlr</i><sup><i>-/-</i></sup>, <i>Myh11Cre</i><sup><i>ERT2</i></sup><i>Abcg1</i><sup><i>fl/fl</i></sup><i>Ldlr</i><sup><i>-/-</i></sup>, and <i>Myh11Cre</i><sup><i>ERT2</i></sup><i>Ldlr</i><sup><i>-/-</i></sup> mice Western-type diet for 16 weeks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Combined <i>SMC-Abca1/Abcg1</i> deficiency increased vasoconstriction in aortic rings induced by the α<sub>1</sub>-AR agonist phenylephrine. Unexpectedly, <i>SMC</i>-<i>Abca1/Abcg1</i> deficiency induced urinary bladder distension by >;20-fold. This was reversed by the α<sub>1</sub>-AR antagonist tamsulosin, indicating its dependence on bladder neck SMC constriction. Moreover, <i>SMC</i>-<i>Abca1/Abcg1</i> deficiency decreased contractile markers and increased macrophage and fibroblast markers in bladder SMCs, indicating SMC transdifferentiation. This was accompanied by free cholesterol accumulation and increased endoplasmic reticulum stress. <i>SMC</i>-<i>Abca1/Abcg1</i> deficiency did not induce thoracic aorta SMC transdifferentiation, presumably due to increased cholesteryl ester accumulation and no endoplasmic reticulum stress in thoracic aorta SMCs. Surprisingly, <i>SMC</i>-<i>Abca1/Abcg1</i> deficiency did not affect atherosclerotic lesion size or composition in the aortic root or brachiocephalic artery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We uncover a new role of SMC cholesterol efflux pathways in suppressing α<sub>1</sub>-AR-mediated vasoconstriction and bladder SMC transdifferentiation, decreasing urinary bladder distension. Our data may provide a mechanistic link for the association between urinary bladder distension and diabetes in humans, particularly because diabetes is associated with decreased cholesterol efflux. <i>SMC</i>-<i>Abca1/Abcg1</i> deficiency did not affect atherosclerotic lesion size or plaque composition, presumably due to low expression of <i>Abca1/Abcg1</i> in intimal SMCs.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39931819/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212031431&v=2.18.0.post9+e462414">39931819</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325103>10.1161/CIRCRESAHA.124.325103</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39931819</guid>
<pubDate>Tue, 11 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Benedek Halmos</dc:creator>
<dc:creator>Anouk M La Rose</dc:creator>
<dc:creator>Daisey Methorst</dc:creator>
<dc:creator>Anouk G Groenen</dc:creator>
<dc:creator>Dalibor Nakládal</dc:creator>
<dc:creator>Venetia Bazioti</dc:creator>
<dc:creator>Mirjam H Koster</dc:creator>
<dc:creator>Niels J Kloosterhuis</dc:creator>
<dc:creator>Azuwerus van Buiten</dc:creator>
<dc:creator>Elisabeth M Schouten</dc:creator>
<dc:creator>Nicolette C A Huijkman</dc:creator>
<dc:creator>Miriam Langelaar-Makkinje</dc:creator>
<dc:creator>Laura Bongiovanni</dc:creator>
<dc:creator>Simon M De Neck</dc:creator>
<dc:creator>Alain de Bruin</dc:creator>
<dc:creator>Hendrik Buikema</dc:creator>
<dc:creator>Leo E Deelman</dc:creator>
<dc:creator>Marius C van den Heuvel</dc:creator>
<dc:creator>Folkert Kuipers</dc:creator>
<dc:creator>Igle Jan de Jong</dc:creator>
<dc:creator>Judith C Sluimer</dc:creator>
<dc:creator>Helle F Jørgensen</dc:creator>
<dc:creator>Robert H Henning</dc:creator>
<dc:creator>Marit Westerterp</dc:creator>
<dc:date>2025-02-11</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>SMC Abca1 and Abcg1 Deficiency Enhances Urinary Bladder Distension but Not Atherosclerosis</dc:title>
<dc:identifier>pmid:39931819</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325103</dc:identifier>
</item>
<item>
<title>Risk of Incident Atrial Fibrillation in Women With a History of Hypertensive Disorders of Pregnancy: A Population-Based Retrospective Cohort Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39931813/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212031431&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Women exposed to HDP in their first delivery have a significantly increased cause-specific hazard ratios of incident AFib compared to their unexposed counterparts, with higher rates observed in subjects exposed to more severe de novo HDP diagnoses as well as chronic hypertension in pregnancy. These findings underscore the need to consider HDP history in risk calculation/stratification for arrhythmic and nonarrhythmic cardiovascular diseases, improve surveillance of traditional and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 11. doi: 10.1161/CIRCULATIONAHA.124.072418. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Hypertensive disorders of pregnancy (HDP) are a major cause of maternal morbidity and mortality and are associated with acute cardiac events in the peripartum period, as well as cardiovascular disease later in life. Despite the robust association between hypertension and atrial fibrillation (AFib), comparatively little is known about HDP and its subtypes as sex-specific risk factors for AFib.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A population-based retrospective cohort study was conducted, including 771 521 nulliparous women discharged for obstetrical delivery of their first live or stillborn singleton infant between 2002 and 2017 in Ontario, Canada. Data were obtained from record-level, coded, and linked population-based administrative databases housed at ICES. Using competing risks Cox proportional hazards regression, we estimated crude and multivariable-adjusted cause-specific hazard ratios and 95% CIs for associations between history of any HDP (and its 6 subtypes), and AFib before death, as well as all-cause mortality without a previous AFib diagnosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Approximately 8% of women were diagnosed with HDP during the 16-year exposure accrual period. The total person-time of follow-up was 7 380 304 person-years, during which there were 2483 (0.3%) incident AFib diagnoses and 2951 (0.4%) deaths. History of any HDP was associated with an increased cause-specific hazard ratios of incident AFib and death without a previous AFib diagnosis (adjusted cause-specific hazard ratios, 1.45 [95% CI, 1.28-1.64] and 1.31 [95% CI, 1.16-1.47], respectively). These associations were observed in relatively young women (median time to event, 7 years postpartum). Associations suggestive of a dose-response relationship were observed, with more severe HDP subtypes and prepregnancy chronic hypertension associated with a 1.5 to 2.2 times higher cause-specific rate of AFib, and a 1.4 to 2.1 times higher cause-specific rate of death compared with no hypertension in pregnancy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Women exposed to HDP in their first delivery have a significantly increased cause-specific hazard ratios of incident AFib compared to their unexposed counterparts, with higher rates observed in subjects exposed to more severe de novo HDP diagnoses as well as chronic hypertension in pregnancy. These findings underscore the need to consider HDP history in risk calculation/stratification for arrhythmic and nonarrhythmic cardiovascular diseases, improve surveillance of traditional and female-specific cardiovascular disease risk factors, and develop targeted prevention strategies to reduce the occurrence and burden of HDP.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39931813/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212031431&v=2.18.0.post9+e462414">39931813</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072418>10.1161/CIRCULATIONAHA.124.072418</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39931813</guid>
<pubDate>Tue, 11 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Amy Johnston</dc:creator>
<dc:creator>William Petrcich</dc:creator>
<dc:creator>Graeme N Smith</dc:creator>
<dc:creator>Deshayne B Fell</dc:creator>
<dc:creator>Peter Tanuseputro</dc:creator>
<dc:creator>Thais Coutinho</dc:creator>
<dc:creator>Jodi D Edwards</dc:creator>
<dc:date>2025-02-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Risk of Incident Atrial Fibrillation in Women With a History of Hypertensive Disorders of Pregnancy: A Population-Based Retrospective Cohort Study</dc:title>
<dc:identifier>pmid:39931813</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072418</dc:identifier>
</item>
<item>
<title>Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39931812/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212031431&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings bring forth the CXCR3-CXCL9/10 axis as an attractive therapeutic target for ICI myocarditis treatment, and more broadly as a druggable pathway in cardiac inflammation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Feb 11. doi: 10.1161/CIRCRESAHA.124.325652. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Immune checkpoint inhibitors (ICIs) are successful in treating many cancers but may cause immune-related adverse events. ICI-mediated myocarditis has a high fatality rate with severe cardiovascular consequences. Targeted therapies for ICI myocarditis are currently limited.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used a genetic mouse model of PD1 deletion (<i>MRL/Pdcd1</i><sup><i>-/-</i></sup>) along with a novel drug-treated ICI myocarditis mouse model to recapitulate the disease phenotype. We performed single-cell RNA-sequencing, single-cell T-cell receptor sequencing, and cellular indexing of transcriptomes and epitopes on immune cells isolated from <i>MRL</i> and <i>MRL/Pdcd1</i><sup><i>-/-</i></sup> mice at serial time points. We assessed the impact of macrophage deletion in <i>MRL/Pdcd1</i><sup><i>-/-</i></sup> mice, then inhibited CXCR3 (C-X-C motif chemokine receptor 3) in ICI-treated mice to assess the therapeutic effect on myocarditis phenotype. Furthermore, we delineated the functional and mechanistic effects of CXCR3 blockade on T-cell and macrophage interactions. We then correlated the results in human single-cell multiomics data from blood and heart biopsy data from patients with ICI myocarditis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Single-cell multiomics demonstrated expansion of CXCL (C-X-C motif chemokine ligand) 9/10+CCR2+ macrophages and CXCR3hi (C-X-C motif chemokine receptor 3 high-expressing) CD8+ (cluster of differentiation) effector T lymphocytes in the hearts of <i>MRL/Pdcd1</i><sup><i>-/-</i></sup> mice correlating with onset of myocarditis development. Both depletion of CXCL9/10+CCR2+ (C-C motif chemokine receptor) macrophages and CXCR3 blockade, respectively, led to decreased CXCR3hi CD8+ T-cell infiltration into the heart and significantly improved survival. Transwell migration assays demonstrated that the selective blockade of CXCR3 and its ligand, CXCL10, reduced CXCR3+CD8+ T-cell migration toward macrophages, implicating this interaction in T-cell cardiotropism toward cardiac macrophages. Furthermore, cardiomyocyte apoptosis was induced by CXCR3hi CD8+ T cells. Cardiac biopsies from patients with confirmed ICI myocarditis demonstrated infiltrating CXCR3+ T cells and CXCL9+/CXCL10+ macrophages. Both mouse cardiac immune cells and patient peripheral blood immune cells revealed expanded TCR s (T-cell receptors) correlating with CXCR3hi CD8+ T cells in ICI myocarditis samples.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings bring forth the CXCR3-CXCL9/10 axis as an attractive therapeutic target for ICI myocarditis treatment, and more broadly as a druggable pathway in cardiac inflammation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39931812/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212031431&v=2.18.0.post9+e462414">39931812</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325652>10.1161/CIRCRESAHA.124.325652</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39931812</guid>
<pubDate>Tue, 11 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Yuhsin Vivian Huang</dc:creator>
<dc:creator>Yin Sun</dc:creator>
<dc:creator>Harrison Chou</dc:creator>
<dc:creator>Noah Wagner</dc:creator>
<dc:creator>Maria Rosaria Vitale</dc:creator>
<dc:creator>Abraham L Bayer</dc:creator>
<dc:creator>Bruce Xu</dc:creator>
<dc:creator>Daniel Lee</dc:creator>
<dc:creator>Zachary Lin</dc:creator>
<dc:creator>Corynn Branche</dc:creator>
<dc:creator>Sarah Waliany</dc:creator>
<dc:creator>Joel W Neal</dc:creator>
<dc:creator>Heather A Wakelee</dc:creator>
<dc:creator>Ronald M Witteles</dc:creator>
<dc:creator>Patricia K Nguyen</dc:creator>
<dc:creator>Edward E Graves</dc:creator>
<dc:creator>Gerald J Berry</dc:creator>
<dc:creator>Pilar Alcaide</dc:creator>
<dc:creator>Sean M Wu</dc:creator>
<dc:creator>Han Zhu</dc:creator>
<dc:date>2025-02-11</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis</dc:title>
<dc:identifier>pmid:39931812</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325652</dc:identifier>
</item>
<item>
<title>Remuscularizing the failing heart in primates</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39930039/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212031431&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Feb 10. doi: 10.1038/s41569-025-01136-z. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39930039/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212031431&v=2.18.0.post9+e462414">39930039</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01136-z>10.1038/s41569-025-01136-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39930039</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Gregory B Lim</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Remuscularizing the failing heart in primates</dc:title>
<dc:identifier>pmid:39930039</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01136-z</dc:identifier>
</item>
<item>
<title>Correction to: 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39929237/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212031431&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 11:ehaf031. doi: 10.1093/eurheartj/ehaf031. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39929237/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212031431&v=2.18.0.post9+e462414">39929237</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf031>10.1093/eurheartj/ehaf031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39929237</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:date>2025-02-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO)</dc:title>
<dc:identifier>pmid:39929237</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf031</dc:identifier>
</item>
<item>
<title>Antagonizing HFpEF by Targeting Fibrosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928720/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212031431&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 11;151(6):396-399. doi: 10.1161/CIRCULATIONAHA.124.072973. Epub 2025 Feb 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928720/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212031431&v=2.18.0.post9+e462414">39928720</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072973>10.1161/CIRCULATIONAHA.124.072973</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928720</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Glynnis Garry Bann</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Antagonizing HFpEF by Targeting Fibrosis</dc:title>
<dc:identifier>pmid:39928720</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072973</dc:identifier>
</item>
<item>
<title>Response by Shen et al to Letter Regarding Article, "Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928719/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212031431&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 11;151(6):e38. doi: 10.1161/CIRCULATIONAHA.124.072690. Epub 2025 Feb 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928719/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212031431&v=2.18.0.post9+e462414">39928719</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072690>10.1161/CIRCULATIONAHA.124.072690</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928719</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Li Shen</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Shen et al to Letter Regarding Article, "Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF"</dc:title>
<dc:identifier>pmid:39928719</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072690</dc:identifier>
</item>
<item>
<title>Major Adverse Cardiovascular Events 1 Year After Discharge in Out-of-Hospital Cardiac Arrest Survivors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928718/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212031431&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 11;151(6):421-423. doi: 10.1161/CIRCULATIONAHA.124.070680. Epub 2025 Feb 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928718/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212031431&v=2.18.0.post9+e462414">39928718</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070680>10.1161/CIRCULATIONAHA.124.070680</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928718</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Sang-Min Kim</dc:creator>
<dc:creator>Sehee Kim</dc:creator>
<dc:creator>Ye-Jee Kim</dc:creator>
<dc:creator>Won Young Kim</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Major Adverse Cardiovascular Events 1 Year After Discharge in Out-of-Hospital Cardiac Arrest Survivors</dc:title>
<dc:identifier>pmid:39928718</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070680</dc:identifier>
</item>
<item>
<title>From the Literature</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928717/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212031431&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 11;151(6):416-417. doi: 10.1161/CIRCULATIONAHA.125.073800. Epub 2025 Feb 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928717/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212031431&v=2.18.0.post9+e462414">39928717</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.125.073800>10.1161/CIRCULATIONAHA.125.073800</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928717</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Tracy Hampton</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>From the Literature</dc:title>
<dc:identifier>pmid:39928717</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.125.073800</dc:identifier>
</item>
<item>
<title>Letter by Tunçez and Gürses Regarding Article, "Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928716/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212031431&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 11;151(6):e37. doi: 10.1161/CIRCULATIONAHA.124.071627. Epub 2025 Feb 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928716/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212031431&v=2.18.0.post9+e462414">39928716</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071627>10.1161/CIRCULATIONAHA.124.071627</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928716</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Abdullah Tunçez</dc:creator>
<dc:creator>Kadri Murat Gürses</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Tunçez and Gürses Regarding Article, "Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF"</dc:title>
<dc:identifier>pmid:39928716</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071627</dc:identifier>
</item>
<item>
<title>Cox Regression Model in Clinical Research: Overview of Key Properties and Interpretation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928715/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212031431&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 11;151(6):337-339. doi: 10.1161/CIRCULATIONAHA.124.072956. Epub 2025 Feb 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928715/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212031431&v=2.18.0.post9+e462414">39928715</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072956>10.1161/CIRCULATIONAHA.124.072956</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928715</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Andrea Bellavia</dc:creator>
<dc:creator>Sabina A Murphy</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cox Regression Model in Clinical Research: Overview of Key Properties and Interpretation</dc:title>
<dc:identifier>pmid:39928715</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072956</dc:identifier>
</item>
<item>
<title>Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928714/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212031431&amp;v=2.18.0.post9+e462414
      <description>Atherosclerotic cardiovascular disease is a major health concern worldwide and requires effective preventive measures. Lp(a) (lipoprotein [a]) has recently garnered attention as an independent risk factor for astherosclerotic cardiovascular disease, with proinflammatory and prothrombotic mechanisms contributing to its atherogenicity. On an equimolar basis, Lp(a) is ~5 to 6 times more atherogenic than particles that have been widely associated with adverse cardiovascular outcomes, such as LDL...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 11;151(6):400-415. doi: 10.1161/CIRCULATIONAHA.124.069210. Epub 2025 Feb 10.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Atherosclerotic cardiovascular disease is a major health concern worldwide and requires effective preventive measures. Lp(a) (lipoprotein [a]) has recently garnered attention as an independent risk factor for astherosclerotic cardiovascular disease, with proinflammatory and prothrombotic mechanisms contributing to its atherogenicity. On an equimolar basis, Lp(a) is ~5 to 6 times more atherogenic than particles that have been widely associated with adverse cardiovascular outcomes, such as LDL (low-density lipoprotein). Lp(a) can enter the vessel wall, leading to the accumulation of oxidized phospholipids in the arterial intima, which are crucial for initiating plaque inflammation and triggering vascular disease progression. In addition, Lp(a) may cause atherothrombosis through interactions between apoA (apolipoprotein A) and the platelet PAR-1 (protease-activated receptor 1) receptor, as well as competitive inhibition of plasminogen. Because Lp(a) is mostly determined on genetic bases, a 1-time assessment in a lifetime can suffice to identify patients with elevated levels. Mendelian randomization studies and post hoc analyses of randomized trials of LDL cholesterol-lowering drugs showed a causal link between Lp(a) concentrations and cardiovascular outcomes, with therapeutic reduction of Lp(a) expected to contribute to estimated cardiovascular risk mitigation. Many Lp(a)-lowering drugs, including monoclonal antibodies, small interfering ribonucleic acids, antisense oligonucleotides, small molecules, and gene editing compounds, are at different stages of clinical investigation and show promise for clinical use. In particular, increased Lp(a) testing and treatment are expected to have a substantial impact at the population level, enabling the identification of high-risk individuals and the subsequent prevention of a large number of cardiovascular events. Ongoing phase 3 trials will further elucidate the cardiovascular benefits of Lp(a) reduction over the long term, offering potential avenues for targeted interventions and improved cardiovascular outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928714/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212031431&v=2.18.0.post9+e462414">39928714</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069210>10.1161/CIRCULATIONAHA.124.069210</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928714</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Antonio Greco</dc:creator>
<dc:creator>Simone Finocchiaro</dc:creator>
<dc:creator>Marco Spagnolo</dc:creator>
<dc:creator>Denise Cristiana Faro</dc:creator>
<dc:creator>Maria Sara Mauro</dc:creator>
<dc:creator>Carmelo Raffo</dc:creator>
<dc:creator>Giuseppe Sangiorgio</dc:creator>
<dc:creator>Antonino Imbesi</dc:creator>
<dc:creator>Claudio Laudani</dc:creator>
<dc:creator>Placido Maria Mazzone</dc:creator>
<dc:creator>Nicola Ammirabile</dc:creator>
<dc:creator>Daniele Giacoppo</dc:creator>
<dc:creator>Davide Landolina</dc:creator>
<dc:creator>Davide Capodanno</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects</dc:title>
<dc:identifier>pmid:39928714</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069210</dc:identifier>
</item>
<item>
<title>Fibroblast growth factor 5: a novel biomarker for familial hypercholesterolaemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928422/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212031431&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This analysis suggests that FGF-5 could be a biomarker to discriminate individuals living with FH from HC individuals.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 10:ehaf045. doi: 10.1093/eurheartj/ehaf045. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Identification of individuals affected by familial hypercholesterolaemia (FH) is suboptimal when genetic tests are unavailable. Relying only on low-density lipoprotein cholesterol (LDL-C) is challenging as it may not allow distinguishing individuals with FH from hypercholesterolaemic (HC) individuals from the general population. The aim of this study was to determine whether biomarkers associated with cardiovascular disease and/or inflammation identify FH individuals and distinguish them from HC individuals.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A panel of 264 proteins in plasma was measured and machine learning was used to search for those that can distinguish FH individuals, either genetically proven (genFH) or clinically diagnosed (clinFH) from HC and control individuals.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Both genFH and clinFH had elevated plasma levels of fibroblast growth factor 5 (FGF-5) compared with controls (mean area under the curve [AUC] >; .990 for both, P &lt; .001) or HC individuals (mean AUC >;.990, P &lt; .001), even after matching for LDL-C levels. An immunoenzymatic assay confirmed that FGF-5 was elevated in genFH and clinFH in all cohorts analysed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This analysis suggests that FGF-5 could be a biomarker to discriminate individuals living with FH from HC individuals.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928422/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212031431&v=2.18.0.post9+e462414">39928422</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf045>10.1093/eurheartj/ehaf045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928422</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Andrea Baragetti</dc:creator>
<dc:creator>Asiiat S Alieva</dc:creator>
<dc:creator>Liliana Grigore</dc:creator>
<dc:creator>Fabio Pellegatta</dc:creator>
<dc:creator>Andrea Lupi</dc:creator>
<dc:creator>Chiara Scrimali</dc:creator>
<dc:creator>Angelo B Cefalù</dc:creator>
<dc:creator>Barbara A Hutten</dc:creator>
<dc:creator>Albert Wiegman</dc:creator>
<dc:creator>Paul Knaapen</dc:creator>
<dc:creator>Michiel J Bom</dc:creator>
<dc:creator>Nick S Nurmohamed</dc:creator>
<dc:creator>Olga Reutova</dc:creator>
<dc:creator>Alexandra Konradi</dc:creator>
<dc:creator>Evgeny Shlyakhto</dc:creator>
<dc:creator>Erik S G Stroes</dc:creator>
<dc:creator>Maurizio Averna</dc:creator>
<dc:creator>Alberico L Catapano</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Fibroblast growth factor 5: a novel biomarker for familial hypercholesterolaemia</dc:title>
<dc:identifier>pmid:39928422</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf045</dc:identifier>
</item>
<item>
<title>Hypertrophic cardiomyopathy: prevalence of disease-specific red flags</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928417/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212031431&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Red flags are a common finding in patients presenting with HCM, most commonly non-cardiac in non-sarcomeric aetiology and cardiac in sarcomeric HCM. Over 34% of RF, most relevant to rare HCM phenocopies, can be potentially detected in a generalist setting. Investing in high-touch-low tech, widespread awareness for HCM-related RF may provide substantial advantage in terms of diagnostic yield and appropriate use of resources.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 10:ehaf026. doi: 10.1093/eurheartj/ehaf026. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The European Society of Cardiology guidelines recommend a systematic search for diagnostic clues or 'red flags' (RFs) in patients with hypertrophic cardiomyopathy (HCM) to better tailor disease management. To date, the prevalence and clinical significance of RF associated with HCM phenotypes in different clinical settings are unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The study cohort comprised 818 patients with a clinical diagnosis of HCM [479 (62%) males, mean age 49 ± 21 years] referred to four European centres. Pre-specified RFs were categorized into one of five domains: (i) family history; (ii) physical examination; (iii) electrocardiography; (iv) echocardiography; and (v) laboratory.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 318 (39%) patients had a pathogenic or likely pathogenic sarcomere gene variant; 240 (29%) a TTR and GLA variant; 154 (19%) a syndromic cause; and 106 (13%) no identifiable cause. In the overall cohort, 2979 RFs were identified. Of these, 1018 (34%) were identifiable from clinical history and examination alone (generalist setting) and 1961 (66%) by 12-lead electrocardiogram and echocardiography (cardiologist's office). Non-sarcomeric patients were diagnosed more often aged &lt;20 and after 60 years (476/500, 95%). Syndromic diseases such as Rasopathies, inherited metabolic disorders, and mitochondrial disorders were diagnosed in neonatal/early childhood (mean age 3 ± 2 years), whereas patients with Danon disease, Friedreich's ataxia, Noonan syndrome, and PRKAG2 cardiomyopathy were identified mostly during adolescence (mean age 16 ± 8 years). Non-cardiac RFs identified by clinical history, physical examination, and routine laboratory testing were most frequent in patients with HCM caused by Rasopathies, inherited metabolic disorders, and mitochondrial disorders (48%, 47%, and 57%, respectively). Physical RFs were almost exclusively observed in patients with a definite non-sarcomeric aetiology [348/350 (99%)]. On the contrary, most RFs associated with geno-positive and geno-negative HCM were derived from electrocardiogram and echocardiography [692/990 (70%) and 332/375 (88%), respectively].</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Red flags are a common finding in patients presenting with HCM, most commonly non-cardiac in non-sarcomeric aetiology and cardiac in sarcomeric HCM. Over 34% of RF, most relevant to rare HCM phenocopies, can be potentially detected in a generalist setting. Investing in high-touch-low tech, widespread awareness for HCM-related RF may provide substantial advantage in terms of diagnostic yield and appropriate use of resources.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928417/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212031431&v=2.18.0.post9+e462414">39928417</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf026>10.1093/eurheartj/ehaf026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928417</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Niccolò Maurizi</dc:creator>
<dc:creator>Emanuele Monda</dc:creator>
<dc:creator>Elena Biagini</dc:creator>
<dc:creator>Ella Field</dc:creator>
<dc:creator>Silvia Passantino</dc:creator>
<dc:creator>Gabriella Dall' Aglio</dc:creator>
<dc:creator>Carlo Fumagalli</dc:creator>
<dc:creator>Panagiotis Antiochos</dc:creator>
<dc:creator>Ioannis Skalidis</dc:creator>
<dc:creator>Maurizio Pieroni</dc:creator>
<dc:creator>Alessia Argirò</dc:creator>
<dc:creator>Francesca Girolami</dc:creator>
<dc:creator>Franco Cecchi</dc:creator>
<dc:creator>Frederic Barbey</dc:creator>
<dc:creator>Pierre Monney</dc:creator>
<dc:creator>Perry M Elliott</dc:creator>
<dc:creator>Juan Pablo Kaski</dc:creator>
<dc:creator>Giuseppe Limongelli</dc:creator>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Hypertrophic cardiomyopathy: prevalence of disease-specific red flags</dc:title>
<dc:identifier>pmid:39928417</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf026</dc:identifier>
</item>
<item>
<title>Tricuspid and mitral regurgitation after mitral transcatheter edge-to-edge repair: a complex interplay</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928369/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212031431&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 10:ehaf044. doi: 10.1093/eurheartj/ehaf044. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928369/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212031431&v=2.18.0.post9+e462414">39928369</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf044>10.1093/eurheartj/ehaf044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928369</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Domenico Angellotti</dc:creator>
<dc:creator>Fabien Praz</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Tricuspid and mitral regurgitation after mitral transcatheter edge-to-edge repair: a complex interplay</dc:title>
<dc:identifier>pmid:39928369</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf044</dc:identifier>
</item>
<item>
<title>Meet the team: new EHJ Editors Matthias Endres, Ulrich Laufs, and Ranil De Silva</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928367/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212031431&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 10:ehae929. doi: 10.1093/eurheartj/ehae929. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928367/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212031431&v=2.18.0.post9+e462414">39928367</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae929>10.1093/eurheartj/ehae929</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928367</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Meet the team: new EHJ Editors Matthias Endres, Ulrich Laufs, and Ranil De Silva</dc:title>
<dc:identifier>pmid:39928367</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae929</dc:identifier>
</item>
<item>
<title>Prognosis following acute myocardial infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928355/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212031431&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 10:ehaf056. doi: 10.1093/eurheartj/ehaf056. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928355/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212031431&v=2.18.0.post9+e462414">39928355</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf056>10.1093/eurheartj/ehaf056</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928355</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Iain B Squire</dc:creator>
<dc:creator>Shirley Sze</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Prognosis following acute myocardial infarction</dc:title>
<dc:identifier>pmid:39928355</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf056</dc:identifier>
</item>





























</channel>
</rss>